ReviewAsia Pacific allergy2020
Drug hypersensitivity reactions in Asia: regional issues and challenges.
Review in Asia Pacific allergy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 34 citations in OpenAlex.
- Impact of a drug allergy education course for non-specialists: Findings from ADAPT-A randomized crossover trial.Allergy · 2025Trial
- Real-World Performance of Non-Allergist-Led Penicillin Allergy Delabeling: Prospective Head-to-Head Comparison of APAAACI vs. PENFAST.Allergy, asthma & immunology research · 2026Article
- Bridging Global Disparities in Drug Allergy Through AI-Assisted Training for Non-Specialists: Findings From the Multinational ADAPT-2 Course.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2026Article
- Investigation into Safety Profiles of Antiepileptic Drugs and Identification of Predictors for Serious Adverse Events: Insights from National Pharmacovigilance Data.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Clinical characteristics and risk factors for escalation to anaphylaxis from non-severe drug hypersensitivity reaction.Clinical and translational allergy · 2025Article
- Clues of HLAs, metabolic SNPs, and epigenetic factors in T cell-mediated drug hypersensitivity reactions.Heliyon · 2024Review
- Identifying the most at-risk age-group and longitudinal trends of drug allergy labeling amongst 7.3 million individuals in Hong Kong.BMC medicine · 2024Article
- Why Pharmacovigilance of Non-steroidal Anti-inflammatory Drugs is Important in India?Endocrine, metabolic & immune disorders drug targets · 2024Review
- APAAACI clinical pathway on direct provocation testing for penicillin allergy delabeling.Asia Pacific allergy · 2023Article
- A new journey ofAsia Pacific allergy · 2023Article
- The Activities of Antimicrobials AgainstInfection and drug resistance · 2023Article
- Updates in SJS/TEN: collaboration, innovation, and community.Frontiers in medicine · 2023Review
- Prevalence and impact of misdiagnosed drug allergy labels among patients with hereditary angioedema.Frontiers in allergy · 2022Article
- Differences in beta-lactam and penicillin allergy: Beyond the West and focusing on Asia-Pacific.Frontiers in allergy · 2022Review
- NSAID Hypersensitivity in the Pediatric Population: Classification and Diagnostic Strategies.Journal of asthma and allergy · 2022Review
- Fatal Events Associated with Adverse Drug Reactions in the Korean National Pharmacovigilance Database.Journal of personalized medicine · 2021Article
- Piperacillin-Tazobactam Allergies: An Exception to Usual Penicillin Allergy.Allergy, asthma & immunology research · 2021Article
- Diagnostic procedures & practices in drug allergy/hypersensitivity: a survey of 13 Asian countries.Asia Pacific allergy · 2020Article
- The 10th Anniversary ofAsia Pacific allergy · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors at 20 institutions in 10 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There are geographical, regional, and ethnic differences in the phenotypes and endotypes of patients with drug hypersensitivity reactions (DHRs) in different parts of the world. In Asia, aspects of drug hypersensitivity of regional importance include IgE-mediated allergies and T-cell-mediated reactions, including severe cutaneous adverse reactions (SCARs), to beta-lactam antibiotics, antituberculous drugs, nonsteroidal anti-inflammatory drugs (NSAIDs) and radiocontrast agents. Delabeling of low-risk penicillin allergy using direct oral provocation tests without skin tests have been found to be useful where the drug plausibility of the index reaction is low. Genetic risk associations of relevance to Asia include human leucocyte antigen (HLA)-B*1502 with carbamazepine SCAR, and HLA-B*5801 with allopurinol SCAR in some Asian ethnic groups. There remains a lack of safe and accurate diagnostic tests for antituberculous drug allergy, other than relatively high-risk desensitization regimes to first-line antituberculous therapy. NSAID hypersensitivity is common among both adults and children in Asia, with regional differences in phenotype especially among adults. Low dose aspirin desensitization is an important therapeutic modality in individuals with cross-reactive NSAID hypersensitivity and coronary artery disease following percutaneous coronary intervention. Skin testing allows patients with radiocontrast media hypersensitivity to confirm the suspected agent and test for alternatives, especially when contrasted scans are needed for future monitoring of disease relapse or progression, especially cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.